Olema Pharmaceuticals (OLMA) Common Equity (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Common Equity of $480.5 million for Q1 2026, up 25.3% year-over-year from $383.5 million in Q1 2025, and little changed quarter-over-quarter from $478.6 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Common Equity (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Common Equity for 7 consecutive years, with $480.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 25.3% year-over-year to $480.5 million; the TTM figure through Mar 2026 stood at $480.5 million (up 25.3% YoY), while the FY2025 annual figure was $478.6 million, up 17.02% from the prior year.
- Common Equity was little changed at $480.5 million in Q1 2026 per OLMA's latest filing, from $478.6 million in the prior quarter.
- Across five years, Common Equity topped out at $480.5 million in Q1 2026 and bottomed at $161.6 million in Q2 2023.
- Historically, Common Equity has averaged $285.2 million across 5 years, with a median of $253.9 million in 2023.
- Annual changes were most pronounced in 2023 — Common Equity slumped 33.99% — and 2025, when it soared 62.26%.
- Olema Pharmaceuticals' Common Equity stood at $197.5 million in 2022, then increased by 28.52% to $253.9 million in 2023, then surged by 61.08% to $409.0 million in 2024, then climbed by 17.02% to $478.6 million in 2025, then advanced by 0.4% to $480.5 million in 2026.
- Business Quant data shows OLMA's Common Equity at $480.5 million in Q1 2026, $478.6 million in Q4 2025, and $307.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 430.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 430.56 Mn |
| Mar 31, 2026 | 480.48 Mn |
| Dec 31, 2025 | 478.56 Mn |
| Sep 30, 2025 | 307.49 Mn |
| Jun 30, 2025 | 345.24 Mn |
| Mar 31, 2025 | 383.45 Mn |
| Dec 31, 2024 | 408.96 Mn |
| Sep 30, 2024 | 198.91 Mn |
| Jun 30, 2024 | 227.16 Mn |
| Mar 31, 2024 | 236.32 Mn |
| Dec 31, 2023 | 253.90 Mn |
| Sep 30, 2023 | 275.13 Mn |
| Jun 30, 2023 | 161.58 Mn |
| Mar 31, 2023 | 174.98 Mn |
| Dec 31, 2022 | 197.55 Mn |
| Sep 30, 2022 | 217.70 Mn |
| Jun 30, 2022 | 236.28 Mn |
| Mar 31, 2022 | 265.09 Mn |
| Dec 31, 2021 | 284.57 Mn |
| Sep 30, 2021 | 300.89 Mn |